Post by Radboudumc Research

7,049 followers

๐“๐ซ๐ž๐š๐ญ๐ข๐ง๐  ๐๐ข๐Ÿ๐Ÿ๐ข๐œ๐ฎ๐ฅ๐ญ ๐›๐š๐œ๐ญ๐ž๐ซ๐ข๐š๐ฅ ๐ข๐ง๐Ÿ๐ž๐œ๐ญ๐ข๐จ๐ง๐ฌ ๐ž๐š๐ซ๐ฅ๐ข๐ž๐ซ, ๐ฌ๐ก๐จ๐ซ๐ญ๐ž๐ซ, ๐š๐ง๐ ๐ฐ๐ข๐ญ๐ก ๐š ๐ก๐ข๐ ๐ก๐ž๐ซ ๐œ๐ก๐š๐ง๐œ๐ž ๐จ๐Ÿ ๐œ๐ฎ๐ซ๐ž ๐Ÿฆ  Clinical microbiologist Jakko van Ingen has been appointed Professor of Diagnostics and antimicrobial therapy of mycobacterial infections at Radboudumc / Radboud University. His work focuses on infections caused by mycobacteria, the bacterial family best known for tuberculosis and leprosy, but also for lesser-known non-tuberculous mycobacteria that can cause serious and hard-to-treat disease. Van Ingen studies how new and existing antibiotics can be used more effectively, while also developing lab models that may help reduce the need for animal testing. His appointment starts on 1 July 2026 for a five-year period. Read more: https://lnkd.in/ek8_QKbH #InfectiousDiseases #Microbiology #Antibiotics #Tuberculosis #Radboudumc #Research #AcademicHealthcare

Post content